Highest-materiality recent filing
Pulmonx Q2 revenue $22.8M (-5% YoY); net loss narrows to $10.1M
Revenue $22.8M, down 5% YoY; U.S. $14.2M (-4%), international $8.6M (-6%; ex-China +12%).
Pulmonx Q1 revenue falls 9% YoY to $20.6M; net loss $13.7M
Worldwide revenue $20.6M (-9% YoY, -12% constant currency); U.S. $13.3M (-7%), international $7.3M (-12%).
Pulmonx enters $60M secured credit facility with Perceptive; draws $40M upfront
$60M senior secured term loan from Perceptive; $40M drawn at closing, up to $20M additional tranches tied to $92.5M and $100M revenue milestones.
Pulmonx Q4 revenue declines 5% YoY; full year up 8%; guides flat FY2026 revenue $90-92M
Q4 2025 revenue $22.6M, down 5% YoY (down 7% constant currency); US revenue fell 11% to $14.1M.
Pulmonx Q3 rev $21.5M (+5%), net loss $14.0M; guides FY rev $89-90M; adds COO role
Worldwide revenue $21.5M (+5% YoY); US $14.0M (+1%), Intl $7.5M (+15%).
Pulmonx reappoints Glen French as CEO and Derrick Sung as COO/CFO; Q3 preliminary revenue ~$21.5M
Glen French (former CEO 2014-2024) reappointed President and CEO; Derrick Sung (former CFO) appointed COO and CFO effective Nov 3, 2025.
Pulmonx Q2 revenue up 15% to $23.9M but cuts FY2025 guidance to $90-92M
Revenue $23.9M (+15% YoY); U.S. $14.7M (+6%), International $9.1M (+32% constant currency +27%).
Pulmonx Q1 2025 revenue $22.5M (+20% YoY); net loss $14.4M; reaffirms FY guidance
Worldwide revenue of $22.5M, up 20% YoY (21% constant currency); U.S. $14.2M (+11%), international $8.3M (+39%).
Record Q4 2024 worldwide revenue $23.8M, up 23% YoY; U.S. revenue $15.9M (+16%), international $7.9M (+42%).
Pulmonx reports record Q2 revenue $20.8M (+21% YoY); net loss narrows to $15.3M
Worldwide revenue $20.8M, up 21% YoY; U.S. revenue $13.9M (+26%); International $6.9M (+12%).
Pulmonx Q1 revenue $18.9M (+30% YoY); net loss narrows to $13.7M
Q1 revenue $18.9M, up 30% YoY (29% constant currency); U.S. revenue $12.9M (+38%).
Glen French resigns as CEO effective March 15; will serve as Senior Advisor until May 1, then remain on Board.
Pulmonx Q4 revenue $19.3M (+25% YoY); full-year 2023 revenue $68.7M (+28% YoY)
Record Q4 U.S. revenue of $13.7M (+45% YoY); added 14 new Zephyr Valve treatment centers.
Pulmonx Q3 revenue $17.7M record +31% YoY; raises FY2023 guidance to $67-68M
Record worldwide revenue $17.7M (+31% YoY); U.S. revenue $11.8M (+41% YoY).
Pulmonx CFO Sung resigns; McKune interim CFO; Q3 revenue prelim ~$17.6M (+30% YoY)
CFO Derrick Sung resigned effective Oct 10, 2023 to pursue other opportunity; no disagreement with company.
Pulmonx Q2 revenue $17.2M (+23% YoY), raises FY2023 guidance to $64-66M
Record worldwide revenue $17.2M, up 23% YoY; US revenue $11.0M up 28% YoY.
Pulmonx Q1 revenue $14.5M (+35% YoY); reaffirms FY 2023 guidance
Worldwide revenue $14.5M, up 35% YoY; U.S. revenue $9.3M (+55% YoY).
Pulmonx Q4 revenue $15.4M (+13% YoY); draws $20M debt; FY23 guidance $63-65M
Q4 2022 revenue $15.4M, up 13% YoY; U.S. revenue $9.5M (+30% YoY).
Pulmonx Q3 revenue $13.5M, cuts FY guidance to $51.5-52.5M; extends credit line to 2027
Q3 revenue $13.5M (+2% YoY, +7% constant currency); US $8.4M (+22%), intl $5.1M (-20%).
Pulmonx Q2 revenue $14.0M (+14% YoY); net loss $14.6M; reaffirms FY outlook
Revenue $14.0M, up 14% YoY (19% constant currency); U.S. revenue $8.6M (+31%).
Pulmonx Q1 revenue $10.8M (+17% YoY); net loss $15.8M; reaffirms FY 2022 guidance
Worldwide revenue $10.8M, up 17% YoY (20% constant currency); US revenue $6.0M (+40%).
Pulmonx Q4 revenue $13.7M (+39% YoY); FY2022 guidance $55M-$60M
Q4 2021 revenue $13.7M, up 39% YoY; FY2021 revenue $48.4M, up 48% YoY.
Pulmonx Q4 revenue $13.7M (+39% YoY); FY rev $48.4M (+48%); guides FY22 $55-60M
Q4 net loss $13.0M ($0.35/sh) vs $9.3M ($0.27/sh) YoY; FY net loss $48.7M ($1.35/sh) vs $32.2M ($3.16/sh).
Pulmonx Q3 revenue $13.3M (+25% YoY); net loss $10.2M; maintains FY guidance $49-51M
Worldwide revenue $13.3M, up 25% YoY ($10.6M Q3 2020); U.S. revenue $6.9M (+28%), international $6.4M (+22%).
Pulmonx Q2 2021 revenue $12.2M (+232% YoY); raises FY guidance to $49-51M
Worldwide revenue $12.2M, up 232% YoY; U.S. revenue $6.6M (+343%), international $5.6M (+157%).
On March 19, 2024, the board of directors of Pulmonx Corporation (the “Company”) appointed Mehul Joshi as the Company’s Chief Financial Officer and Principal Financial and Accounting Officer, effective upon commencement of his employment with the Company on April 3, 2024 (the “Effective Date”).
On February 20, 2024, Glendon E. French resigned as President and Chief Executive Officer of Pulmonx Corporation (the “Company”), effective as of March 15, 2024
On February 19, 2024, the Company’s board of directors appointed Steven S. Williamson as the Company’s President and Chief Executive Officer and a Class II member of the board of directors, each as of the Effective Date.
On October 6, 2023, Derrick Sung, Ph.D., Chief Financial Officer of the Company, stepped down from his position, effective October 10, 2023 (the “ Effective Date ”), to pursue a new business opportunity.
John McKune, Vice President, Corporate Controller of the Company, was appointed by the Board of Directors of the Company (the “ Board ”) to serve as the Interim Chief Financial Officer of the Company, effective as of the Effective Date.
Effective as of July 29, 2021, the Company’s Board of Directors (the “Board”) appointed Ms. Alissa Hsu Lynch and Ms. Tiffany Sullivan and to serve as Class I directors of the Board.
Effective as of July 29, 2021, the Company’s Board of Directors (the “Board”) appointed Ms. Alissa Hsu Lynch and Ms. Tiffany Sullivan and to serve as Class I directors of the Board.
Max materiality 0.85 · Median 0.70 · Most common event earnings